EGFRt/19-28z/4-1BBL CAR T cells
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
April 02, 2025
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026
Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology
September 28, 2023
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology
April 07, 2023
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2023 ➔ Mar 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
April 04, 2022
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2022 ➔ Mar 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
April 02, 2021
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1; N=39; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
January 06, 2021
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
(clinicaltrials.gov)
- P1; N=37; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Mar 2021 ➔ Mar 2022; Trial primary completion date: Mar 2021 ➔ Mar 2022
Clinical • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 6
Of
6
Go to page
1